Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide CKA18N for inhibiting angiogenesis and application thereof

An angiogenesis and purpose technology, applied in the field of biomedicine, can solve the problem of high price and achieve the effect of inhibiting angiogenesis and inhibiting the formation of blood vessels

Active Publication Date: 2019-04-09
LINK HEALTH GRP
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs are expensive, and there is still a large demand for new anti-angiogenesis drugs in the medical field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide CKA18N for inhibiting angiogenesis and application thereof
  • Polypeptide CKA18N for inhibiting angiogenesis and application thereof
  • Polypeptide CKA18N for inhibiting angiogenesis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Synthesis of polypeptide CKA18N

[0031] CKA18N (SEQ ID NO: 1) was synthesized by a conventional solid-phase process, and the purity of the synthesized peptide was >98%.

Embodiment 2

[0032] Example 2 Angiogenesis of human umbilical vein endothelial cells (HUVEC cells)

[0033] Primary culture of human umbilical vein endothelial cells (HUVEC, Human umbilical vein endothelial cells), added 3 μg / ml, 10 μg / ml, 30 μg / ml, 100 μg / ml, 300 μg / ml and 1000 μg / ml of polypeptide CKA18N treatment, cultured in Matrigel, After 4 to 6 hours, the blood vessel formation was observed and counted. PBS was used as a negative control, and 100 μg / ml bevacizumab was used as a positive control.

[0034] The result is as figure 1 with 2 shown by figure 1 , 2 It can be seen that compared with the negative control PBS, the polypeptide CKA18N has a significant inhibitory effect on the angiogenesis of HUVEC (**: p<0.01), and the dose-effect relationship is significant.

Embodiment 3

[0035] Example 3 Transwell detection of cell migration ability

[0036] Collect the cells treated with different drugs in Example 2, count 1×10 5 The cells were resuspended with serum-free medium, added to the upper chamber of the Transwell cell culture plate, and 600 μl complete medium was added to the lower chamber. At 37°C, 5% CO 2 After incubating for 12-48 hours in the environment, take out the small chamber, wipe off the cells in the upper chamber with a cotton swab, fix with 4% paraformaldehyde for 20mins, wash once with PBS, stain with crystal violet for 10mins, wash once with PBS, and observe under the microscope whether the cells pass through the small chamber. If the holes pass through, terminate other experimental groups, and take pictures for statistics.

[0037] The result is as image 3 with 4 shown by image 3 , 4 It can be seen that the polypeptide CKA18N can inhibit the migration of HUVEC in a dose-dependent manner (**: p<0.01).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a polypeptide CKA18N and application of the polypeptide CKA18N or pharmaceutically acceptable salt thereof to preparation of drugs for treating and / or preventing diseases caused by angiogenesis. The polypeptide CKA18N has an amino acid sequence which has a sequence consistency of 13.18 or more when being compared with SEQ ID NO. 1. The invention furthermore discloses a pharmaceutical composition for treating diseases caused by angiogenesis; and the pharmaceutical composition comprises the polypeptide CKA18N, or the pharmaceutically acceptable salt of the polypeptide CKA18N, and a pharmaceutically acceptable carrier. Compared with the existing drugs for inhibiting angiogenesis, the polypeptide CKA18N (SEQ ID NO. 1) has the following advantages: (1) the CKA18N is as long as 18 amino acids, is easy to synthesize and low in cost; (2) the polypeptide CKA18N has a remarkable effect of inhibiting angiogenesis; and (3) the polypeptide CKA18N has relatively good solubility in water and is easily administered by injection.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a polypeptide CKA18N for inhibiting angiogenesis and its application. Background technique [0002] Angiogenesis refers to the formation, development and growth of new blood vessels. Generally speaking, angiogenesis is strictly regulated, mainly through the delicate balance between factors that induce angiogenesis (such as vascular endothelial growth factor VEGF, etc.) and inhibitory factors. When this balance is disturbed, pathological angiogenesis usually results. Angiogenesis is a dynamic, multi-step process. It is now known that many diseases are related to angiogenesis disorders, such as cancer, ocular vascular abnormalities, infection, cardiovascular diseases, and injuries. Therefore, it is of great significance to study angiogenesis inhibitors. The main process of angiogenesis includes degradation of vascular basement membrane, activation, proliferation and migration...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08A61K38/10A61P27/02A61P9/10A61P35/00A61P3/10
CPCA61P3/10A61P9/10A61P27/02A61P35/00C07K7/08A61K38/00
Inventor 宋燕张时群许元生卢肖宇汤宇晴苏博雅
Owner LINK HEALTH GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com